Summary of the Interim Report
Net sales of 6.5 MSEK (0.0 MSEK)
Other income amounted to 0.1 MSEK (0.1 MSEK)
First quarter of 2023
- R&D costs for the period amounted to 8.6 MSEK (17.2 MSEK)
- Profit after tax amounted to -5.4 MSEK (-20.3 MSEK)
- Earnings per share for the quarter amounted to
- Cash flow from operating activities amounted to -9.1 MSEK (-19.8 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 13.1 MSEK (23.0 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 70.7 MSEK (72.1 MSEK)
- Klaria receives payment of 2.6 MSEK from
For more information, visit the
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99
This is
Klaria (
https://news.cision.com/klaria-pharma-holding-ab/r/klaria-interim-report-q1-2023,c3769079
https://mb.cision.com/Main/12655/3769079/2057967.pdf
(c) 2023 Cision. All rights reserved., source